President and CEO of Pharmaceutics International, Inc. (Pii), John Fowler, reacts to the agility and flexibility needed to support the development and manufacture of today's complex biotherapeutics.
AST’s VP of Business Development, Josh Russell, discusses the company’s impact on the pharmaceutical industry using innovative fill/finish equipment.
Shawn Opatka, Vice President & General Manager of Life Sciences at Honeywell, discusses how the company stands out in an industry that constantly evolves.
At a recent INTERPHEX conference, Laura Moody (Director of Product Management, Pharma North America, Syntegon) shared some insights into current trends in the pharmaceutical industry, including the EU Annex 1.
Joe Payne, Scorpius BioManufacturing, comments on the unique needs of today's biopharmaceutical companies looking to develop and manufacture small-volume, early-stage large molecules.
Ray Guidotti, Chief Operating Officer at Simtra BioPharma Solutions, talks about the company's strategic development and how it supports customers with a focus on excellence.
Adam Covitt, President of Federal Equipment Company, discusses how the company enables CDMO successes with its Techceuticals and PharmParts business brands.
Peter DeYoung, CEO, Piramal Pharma Solutions, talks about recent company achievements and key offerings, as well as current industry trends.
Josh Hirshenhorn (Sales Representative, Rees Scientific) explains current challenges faced by pharmaceutical and biotech companies and how Rees' continuous monitoring systems offer solutions.
Meeta B. Kratz (Global Vice President, Product Management & Marketing, Lonza Capsule and Health Ingredients) talks about Lonza's future and how that works in tandem to meet client needs.
Explore how Rentschler Biopharma duels biopharmaceutical innovation, spanning from pioneering biological products to cutting-edge cell and gene therapies
Hayley Crowe, Executive VP & GM at Ecolab Global Life Sciences, talks about the company's services and how they relate to trends in bioprocessing and purification.
Drs Dawn Dufield and Dominic Warrino, KCAS Bioanalytical and Biomarker Services, share expertise on using Hybrid LC-MS versus LBA for bioanalytical analysis.
Sean Knight, Simtra BioPharma Solutions, reacts to the company's global expansion efforts and investment in sterile fill/finish.
Franco Negron, CEO, Simtra BioPharma Solutions, discusses the company's expertise in supporting the development and manufacture of sterile injectables, its integrated approach to project management, and his expectations regarding the company's future in the industry.
Bradley Grobler, Vice President of Sales, Pharma & Biopharma Europe, describes how Actylis meets global demands for (bio)pharmaceutical development and manufacturing programs during CPhI 2023.
Shaukat Ali, PhD, Senior Director of Scientific Affairs and Technical Marketing, Ascendia Pharmaceuticals, highlights the benefits of the company’s nanotechnologies in supporting formulation development of poorly soluble molecules.
Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals, highlights traits that a (bio)pharmaceutical company look for when identifying a CDMO to support drug development and manufacturing programs.
Ascendia Pharmaceuticals CEO, Jim Huang, describes how new opportunities in formulation development complement the company’s previous work in developing novel nanotechnologies to support biopharmaceutical development.
Societal™ CDMO's J. David Enloe and Erica Raether discuss the fundamentals of maintaining a strong company culture during times of change.
Wesley Tatum, PhD (Principal Engineer, Process & Product Development, Serán Bioscience) shares insights surrounding formulation and process development that focus on the future of the industry.
Leverage artificial intelligence (AI) for a more streamlined GMP manufacturing process.
LIGHTHOUSE Instruments introduces new technology for robust headspace data generation and areas of application.
Dr Seán McMahon explains how Ashland’s Viatel™ bioresorbable work and rationalizes why formulators should consider using in the development of long acting injectables and implants.
Enrico Barichello, Product Manager for the Syringe Platform at Stevanato Group, discusses the risks associated with the interaction between primary packaging and complex novel therapeutics and describes how to prevent or manage concerns utilizing newer, pre-sterilized syringe systems that have more unique characteristics.
Catalent's Martin De Brauwere and Maria Lopez react to cell therapy innovations and highlight strategies to optimize the drug development and manufacturing process with assistance from a CDMO.
